Briacell Therapeutics CORP 10-Q quarterly reports

BriaCell Therapeutics Corp. reported increased operating expenses and a wider net loss for the third quarter of fiscal year 2026, driven by significant investments in research and development for its immunotherapy candidates.

BriaCell Therapeutics reports increased net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its oncology pipeline.

BriaCell Therapeutics Corp. reported a substantial increase in cash and a swing to positive working capital driven by multiple equity offerings, while continuing to advance its Bria-IMT and Bria-OTS immunotherapy programs for metastatic breast cancer despite widening net losses.

BriaCell Therapeutics Corp. announces its financial results for the quarter ended January 31, 2025, alongside updates on its clinical trials and recent financial activities, including multiple offerings and a reverse stock split.

BriaCell Therapeutics Corp. reported its financial results for the first quarter of fiscal year 2025, showing a net loss but also highlighting advancements in its pivotal Phase 3 breast cancer trial and recent capital raises.

BriaCell Therapeutics reported its Q3 2024 financial results, showing a net profit due to a significant decrease in warrant liability, while also detailing progress in its clinical trials and a recent capital raise.

BriaCell Therapeutics Corp. reports a net loss of $5.375 million for the six months ended January 31, 2024, driven by increased research and development expenses, particularly for its Bria-IMT Phase 3 trial.